AC Immune (NASDAQ:ACIU) Receives Consensus Rating of “Hold” from Analysts

Posted by on Aug 2nd, 2026

AC Immune (NASDAQ:ACIU – Get Free Report) has been assigned an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $7.50.

ACIU has been the subject of a number of recent analyst reports. Weiss Ratings downgraded AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Monday, May 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research note on Wednesday, July 1st.

View Our Latest Report on ACIU

Insider Activity at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $2.79, for a total value of $27,900.00. Following the transaction, the chief executive officer directly owned 3,820,288 shares in the company, valued at approximately $10,658,603.52. This represents a 0.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of AC Immune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in shares of AC Immune in the fourth quarter worth $586,000. Dimensional Fund Advisors LP increased its position in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after acquiring an additional 176,701 shares during the period. Acadian Asset Management LLC raised its stake in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after acquiring an additional 172,796 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in AC Immune in the second quarter valued at $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Price Performance

ACIU stock opened at $2.19 on Friday. AC Immune has a 52-week low of $2.03 and a 52-week high of $4.00. The company has a quick ratio of 1.02, a current ratio of 0.87 and a debt-to-equity ratio of 0.11. The stock has a market cap of $222.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.57. The business has a fifty day moving average of $2.42 and a two-hundred day moving average of $2.81.

AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.40 million for the quarter, compared to analyst estimates of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. As a group, research analysts anticipate that AC Immune will post -0.84 earnings per share for the current year.

AC Immune Company Profile

(Get Free Report)

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

Featured Stories

Analyst Recommendations for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.